Roche's Wilserdly-Everolimus Gets FDA Approval For ESR1-Mutated Advanced Breast Cancer
(RTTNews) - Roche Holding AG (RHHBY) said the U.S. Food and Drug Administration approved Wilserdly, or giredestrant, with everolimus for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.